Metabolic dysfunction–associated steatotic liver disease (MASLD) is driven by complex immune and inflammatory mechanisms. Visceral adiposity, a key contributor, worsens inflammation, immune dysregulation, and insulin resistance.
Objective:
This study examines correlations between inflammatory genes, insulin resistance markers, and inflammatory markers across visceral adiposity levels in patients with MASLD.
Methods:
This cross-sectional study included 102 patients with MASLD. Assessments included body mass index, visceral adiposity index (VAI), a body shape index (ABSI), inflammatory markers, gene expression from peripheral white blood cells, and serologic inflammatory proteins. We calculated insulin resistance markers, such as homeostasis model assessment–insulin resistance index (HOMA-IR), triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio, triglyceride-glucose (TyG) index, and neutrophil-to-HDL ratio (NHR). Pearson correlation coefficients evaluated parameter associations between low and high VAI and ABSI groups.
Results:
The higher VAI group presented with some elevated markers, such as HOMA-IR (5.21 ± 3.42 vs. 4.34 ± 4.62), TG/HDL-C (4.08 ± 1.97 vs. 2.20 ± 1.07), TyG (9.03 ± 0.48 vs. 8.70 ± 0.51), and NHR (1.86 ± 0.75 vs. 1.45 ± 0.64) compared with the low VAI group, indicating potentially greater insulin resistance and systemic inflammation. Monocyte chemoattractant protein-1 and interleukin-6 genes were strongly correlated in the low VAI group (R = 0.94, P < 0.001) but more weakly correlated in the high VAI group (R = 0.63, P < 0.001).
Conclusion:
These findings highlight differential immune changes across visceral adiposity levels in MASLD, supporting the need for tailored interventions based on adiposity profiles.
YounossiZM, KoenigAB, AbdelatifD, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64(1):73–84; doi: 10.1002/hep.28431
2.
MeyerM, SchwärzlerJ, JukicA, et al.Innate immunity and MASLD. Biomolecules, 2024; 14(4):476.
3.
HubyT, GautierEL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol, 2022; 22(7):429–443; doi: 10.1038/s41577-021-00639-3
4.
JinS, ChinJ, SeeberS, et al.TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation. Mucosal Immunol, 2013; 6(5):886–899; doi: 10.1038/mi.2012.124
5.
HouY, WangY, ChenJ, et al.Dual roles of tumor necrosis factor superfamily 14 in antiviral immunity. Viral Immunol, 2022; 35(9):579–585; doi: 10.1089/vim.2022.0070
6.
OtterdalK, HaukelandJW, YndestadA, et al.Increased serum levels of LIGHT/TNFSF14 in nonalcoholic fatty liver disease: Possible role in hepatic inflammation. Clin Transl Gastroenterol, 2015; 6(7):e95; doi: 10.1038/ctg.2015.23
7.
WangS, YinJ, LiuZ, et al.Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated Steatotic liver disease. Life Sci, 2024; 359:123211; doi: 10.1016/j.lfs.2024.123211
8.
BashamA, RafatiS, Hosseini TeshniziS, et al.Application of the Chinese Visceral Adiposity Index in the diagnosis of hepatic steatosis and liver fibrosis: A cross-sectional study. Hepat Mon, 2023; 23(1):e150455; doi: 10.5812/hepatmon-150455
9.
PettaS, AmatoMC, Di MarcoV, et al.Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2012; 35(2):238–247; doi: 10.1111/j.1365-2036.2011.04929.x
10.
KuangM, ShengG, HuC, et al.The value of combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver disease. Lipids Health Dis, 2022; 21(1):104; doi: 10.1186/s12944-022-01717-8
ZyśkB, OstrowskaL, Smarkusz-ZarzeckaJ, et al.Evaluation of the diagnostic utility of selected serum adipokines and cytokines in subjects with MASLD - a pilot study. Nutrients, 2024; 16(9):1381; doi: 10.3390/nu16091381
13.
DongT, LiJ, LiuY, et al.Roles of immune dysregulation in MASLD. Biomed Pharmacother, 2024; 170:116069; doi: 10.1016/j.biopha.2023.116069
14.
LinY-H, WangC-H, HuangY-H, et al.Models incorporating physical, laboratory and gut metabolite markers can be used to predict severe hepatic steatosis in MAFLD patients. Kaohsiung J Med Sci, 2024; 40(12):1095–1105; doi: 10.1002/kjm2.12904
15.
HallalPC, VictoraCG. Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc, 2004; 36(3):556; doi: 10.1249/01.mss.0000117161.66394.07
16.
Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ) – Short and Long Forms. Version 2.0. Available from: https://sites.google.com/view/ipaq/score
17.
IshiyamaD, YamadaM, MakinoA, et al.The cut-off point of short physical performance battery score for sarcopenia in older cardiac inpatients. Eur Geriatr Med, 2017; 8(4):299–303; doi: 10.1016/j.eurger.2017.05.001
18.
VellasB, GuigozY, GarryPJ, et al.The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition, 1999; 15(2):116–122; doi: 10.1016/S0899-9007(98)00171-3
19.
TsouM-T, ChangY-C, HsuC-P, et al.Visceral adiposity index outperforms conventional anthropometric assessments as predictor of diabetes mellitus in elderly Chinese: A population-based study. Nutr Metab (Lond), 2021; 18(1):87; doi: 10.1186/s12986-021-00608-6
20.
ZhaoQ, ZhangK, LiY, et al.Capacity of a body shape index and body roundness index to identify diabetes mellitus in Han Chinese people in Northeast China: A cross-sectional study. Diabet Med, 2018; 35(11):1580–1587; doi: 10.1111/dme.13787
21.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28(7):412–419; doi: 10.1007/bf00280883
22.
LiS, FengL, DingJ, et al.Triglyceride glucose-waist circumference: The optimum index to screen nonalcoholic fatty liver disease in non-obese adults. BMC Gastroenterol, 2023; 23(1):376; doi: 10.1186/s12876-023-03007-8
23.
ChenQ, HuP, HouX, et al.Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol, 2024; 23(1):232; doi: 10.1186/s12933-024-02343-7
24.
StefaniukP, SzymczykA, PodhoreckaM. The neutrophil to lymphocyte and lymphocyte to monocyte ratios as new prognostic factors in hematological malignancies - A narrative review. Cancer Manag Res, 2020; 12:2961–2977; doi: 10.2147/cmar.s245928
25.
LiuK, TangS, LiuC, et al.Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk. Front Immunol, 2024; 15:1337241; doi: 10.3389/fimmu.2024.1337241
HuangZ, NgK, ChenH, et al.Validation of controlled attenuation parameter measured by FibroScan as a novel surrogate marker for the evaluation of metabolic derangement. Front Endocrinol (Lausanne), 2021; 12:739875; doi: 10.3389/fendo.2021.739875
28.
SterlingRK, LissenE, ClumeckN, et al.; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006; 43(6):1317–1325; doi: 10.1002/hep.21178
29.
SrivastavaA, GailerR, TanwarS, et al.Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol, 2019; 71(2):371–378; doi: 10.1016/j.jhep.2019.03.033
30.
KanwalF, Neuschwander-TetriBA, LoombaR, et al.Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease. Hepatology, 2024; 79(5):1212–1219; doi: 10.1097/hep.0000000000000670
31.
LiuQ, RenY, HeL, et al.Analysis of gene expression and immune infiltration in white adipose tissue of patients with obesity: Bioinformatics analysis and meta-analysis [Preprint]. Res Sq, 2024.
32.
MukherjeeS, SkredeS, HaugstøylM, et al.Peripheral and central macrophages in obesity. Front Endocrinol (Lausanne), 2023; 14:1232171; doi: 10.3389/fendo.2023.1232171
33.
DuanY, PanX, LuoJ, et al.Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol, 2022; 13:880298; doi: 10.3389/fimmu.2022.880298
34.
BertolaA, BonnafousS, AntyR, et al.Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One, 2010; 5(10):e13577; doi: 10.1371/journal.pone.0013577
35.
SinghP. Evaluation of pro-inflammatory markers IL-6 and TNF-a and their correlation with non-alcoholic fatty liver disease. Journal of Advanced Research in Medicine, 2019; 06:1–6; doi: 10.24321/2349.7181.201906
36.
KurbatovaIV, TopchievaLV, DudanovaOP, et al.Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis. Ter Arkh, 2019; 91(4):21–27; doi: 10.26442/00403660.2019.04.000057
37.
BingC. Is interleukin-1β a culprit in macrophage-adipocyte crosstalk in obesity? Adipocyte, 2015; 4(2):149–152; doi: 10.4161/21623945.2014.979661
38.
GaoD, MadiM, DingC, et al.Interleukin-1β mediates macrophage-induced impairment of insulin signaling in human primary adipocytes. Am J Physiol Endocrinol Metab, 2014; 307(3):E289–E304; doi: 10.1152/ajpendo.00430.2013
39.
WuH, BallantyneCM. Metabolic inflammation and insulin resistance in obesity. Circ Res, 2020; 126(11):1549–1564; doi: 10.1161/CIRCRESAHA.119.315896
40.
KajikawaM, MaruhashiT, KishimotoS, et al.A Body Shape Index as a simple anthropometric marker of abdominal obesity and risk of cardiovascular events. J Clin Endocrinol Metab, 2024; 109(12):3272–3281; doi: 10.1210/clinem/dgae282
41.
LiuY, LuX, LiX, et al.High-fat diet triggers obesity-related early infiltration of macrophages into adipose tissue and transient reduction of blood monocyte count. Mol Immunol, 2020; 117:139–146; doi: 10.1016/j.molimm.2019.11.002
42.
PorscheCE, DelpropostoJB, GeletkaL, et al.Obesity results in adipose tissue T cell exhaustion. JCI Insight, 2021; 6(8):e139793; doi: 10.1172/jci.insight.139793
43.
SimBC, KangYE, YouSK, et al.Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis. Cell Death Dis, 2023; 14(9):618; doi: 10.1038/s41419-023-06146-8
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
